1	A unique gene expression signature in visceral adipose tissue identifies a high
2	blood pressure group in patients with Cushing's syndrome
3	Ulrich Stifel <sup>1*</sup> , Frederick Vogel <sup>2*</sup> , Giorgio Caratti <sup>1,3</sup> , Martin Reincke <sup>2#</sup> , Jan Tuckermann <sup>1#</sup>
4	<sup>1</sup> Institute of Comparative Molecular Endocrinology (CME), Ulm University, Ulm, Germany
5	<sup>2</sup> Medizinische Klinik und Poliklinik IV, University Hospital, LMU Munich, Munich, Germany
6	<sup>3</sup> Oxford Centre for Diabetes, Endocrinology and Metabolism, University of Oxford, UK
7	
8	
9	
10	
11	
12	
13	
14	
15	
16	
17	
18	
19	
20	
21	
22	
23	
24	
25	*These authors contributed equally
26	*Corresponding authors:
27	Martin Reincke: martin.reincke@med.uni-muenchen.de
28	Jan Tuckermann: jan.tuckermann@uni-ulm.de
29	Short title: Adipose signature and blood pressure in Cushing.
30 31	<b>Keywords:</b> Cushing's syndrome, adipose tissue, hypertension, renin, cortisol, ACTH, adrenal hyperfunction, Cushing's disease
32	NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

# 33 Abstract

34 Cushing's syndrome (CS) is a rare disease caused by excess cortisol levels with high cardiovascular 35 morbidity and mortality. Hypertension is a frequent feature of Cushing's syndrome, promoting 36 hypercortisolism-associated cardiovascular events. Adipose tissue is a highly plastic tissue with most 37 of the major cell types strongly affected in their function by the excess cortisol exposure. We hypothesized that the molecular and cellular changes of visceral adipose tissue (VAT) in response to 38 39 cortisol excess can impact on systemic blood pressure levels in patients with CS. We, therefore, investigated gene expression signatures in VAT from patients with CS collected during curative adrenal 40 41 surgery identifying significant alterations. During active CS we observed a strong downregulation of gene programs associated with immunity and inflammation in the VAT. In addition, we observed an 42 43 clustering of the patients based on VAT gene expression profiles into two groups (CS<sup>Low</sup> and CS<sup>High</sup>) according to blood pressure levels. The two clusters showed significant differences in gene expression 44 45 pattens of the renin-angiotensin-aldosterone-system (RAAS). Renin (REN) was the strongest regulated 46 gene compared to control patients and its expression correlated with increased blood pressure 47 observed in our patients while systemic renin plasma levels were suppressed indicative of an abnormal 48 blood pressure and volume status in response to VAT RAAS activation. Here we show for the first time a relevant contribution of the local RAAS system on systemic blood pressure levels in patients with CS. 49 Patients from the CS<sup>High</sup> group had still a significant increased blood pressure levels 6 months into 50 remission, highlighting the importance of local tissue effects on long-term systemic effects observed 51 52 in CS.

53

## 55 Introduction

56 Endogenous Cushing's syndrome (CS) is a rare disease affecting 1-3 people per million per year [1]. It 57 is caused by chronic excessive secretion of cortisol by the adrenal glands. Consequently, patients have 58 increase morbidity and mortality, and this is mainly due to cardiovascular and cerebrovascular events 59 as well as infectious complications. According to the European Cushing's Registry ERCUSYN, mortality is highest around the time of diagnosis until 90 days following start of therapy [2]. In Denmark, patients 60 61 with active CS had a seven-fold increased risk of venous thromboembolism because of hypercoagulable state, a six-fold increased risk of heart failure, and a four-to-five-fold risk of stroke, 62 63 compared with the background population [3]. A nation-wide cohort study from Sweden demonstrated similar results, with increased cardiovascular morbidity starting up to 3 years prior 64 65 diagnosis, and elevated risks for stroke and myocardial infarction even years after biochemical remission [4]. 66

Up to 85% of patients with CS have hypertension at diagnosis, and 9% may require hospital admission because of hypertensive crisis [5]. Prevalence of hypertension depends on subtype, duration of hypercortisolism, age, and co-existing metabolic comorbidities, such as diabetes mellitus, obesity and other components of the metabolic syndrome [6-8]. Whether a sex-specific difference exists in hypercortisolism-associated hypertension remains controversial [9, 10]. Interestingly, no correlation between blood pressure values and cortisol levels was observed [11-13]. However, hypertension has been reported to be an independent factor associated with increased mortality in CS [14, 15].

74 The pathophysiology of CS-related hypertension is complex and not well understood. The supposed 75 pathogenetic mechanisms include a broad spectrum of contributing factors, such as mineralocorticoid 76 receptor activation, vasoactive factors, increased vascular reactivity to vasoconstrictors as well as 77 activation and/or modulation of the renin-angiotensin system (RAS) [5, 11, 13, 16]. Since phenotypically the visceral adipose tissue (VAT) is massively increased in CS, and visceral obesity has a 78 79 major impact on the clinical phenotype during active CS as well as the persistence of several 80 comorbidities including hypertension [17-21], we assumed that auto- and paracrine factors of the VAT 81 may be relevant for systemic blood pressure regulation [22-24]. Therefore, we hypothesize that factors from VAT, especially components of the RAS, can modulate systemic blood pressure levels in patients 82 83 with CS, independent of pharmacological intervention. To prove our hypothesis, we studied VAT from 84 patients with CS obtained during curative adrenal surgery and investigated the association between 85 expression of the local RAS in VAT using RNAseq and immunohistochemistry, and the hypertension phenotype at time of diagnosis as well as following curative surgery. 86

#### 88 Patients and methods

#### 89 Patients

90 A total of 17 patients with an unilateral adrenocortical tumor who underwent adrenalectomy at the 91 Ludwig Maximilians University Munich were included in this study. Of these, 12 patients were 92 diagnosed with overt adrenal Cushing's syndrome due to cortisol-producing adrenal adenoma (CPA) 93 and 5 with nonfunctioning adrenal tumor (NFAT) who served as controls. All patients with adrenal CS 94 had typical signs and symptoms at the time of diagnosis. Diagnosis and subtype differentiation were 95 based on the criteria recommended by current clinical practice guidelines [1, 25], following standard 96 operational procedures as reported previously [18, 26]. NFAT was confirmed by at least one normal biochemical test for endogenous hypercortisolism and the absence of typical hypercortisolism-97 98 associated signs and symptoms. Exclusion criteria were age above 70 or below 18 years, mild 99 autonomous cortisol secretion, CS due to adrenocortical carcinoma, bilateral adrenal masses, 100 persistent disease after surgery and adrenostatic therapy prior to surgery. Because of the higher 101 prevalence of CPAs in women [27, 28], and thus more tissue samples available, only female patients 102 were included in the study. The number of cases available and tissue samples stored during the 103 inclusion period determined the sample size of female patients with overt adrenal CS and NFAT. 104 Periadrenal adipose tissue was separated from the adrenal gland immediately after receipt of the 105 resectate and stored at -80°C. Because of the limited availability of paraffin-embedded periadrenal 106 adipose tissue, we took tissues of additional patients for histological analyses difered (CPA n=10, NFAT 107 n=5).

Patients with CS underwent clinical and biochemical assessment at the time of diagnosis before surgery and again 6 months following adrenalectomy. Successful surgery outcome was confirmed by clinical and biochemical disease remission including the presence of adrenal insufficiency postoperatively. During the adrenal insufficiency phase, all patients received standard glucocorticoid replacement therapy, consisting of 20-25 mg hydrocortisone per day.

The study was performed as part of the German Cushing's registry. Patients were diagnosed and underwent adrenalectomy between 2012 and 2021 at the Munich center of the German Cushing's registry. The German Cushing's registry (NeoExNet, No. 152-10) was approved by the LMU ethics committee, and all patients gave written informed consent.

117

## 118 Blood pressure measurements

Blood pressure measurements were taken during the visits at the time of diagnosis and 6 months after
 successful surgery. Blood pressure was measured in a sitting position, using an automatic oscillometric

device, after 5 minutes of rest. The mean value of three consecutive measurements was used in theanalysis.

123

# 124 Measurement of blood and serum parameters

125 Venous blood samples were taken after overnight fast at the time of diagnosis. Hormonal laboratory 126 analyses included serum cortisol, aldosterone and plasma renin concentration, cortisol after overnight 127 1 mg suppression, urinary free cortisol measurements and late-night salivary cortisol determinations. 128 All lab tests were performed in the endocrine laboratory, Department of Medicine IV, and in the 129 Clinical Laboratory Department, University Hospital Munich. Measurements of serum aldosterone and 130 renin concentrations were made in one run at the end of the inclusion period, reducing analytical 131 variability. Further biochemical parameters were performed in the Institute of Laboratory Medicine, 132 University Hospital Munich, using standard methods.

133

# 134 RNA-seq

135 Visceral adipose tissue (VAT)-biopsy from 14 patients with adrenal CS and 5 with NFAT who served as 136 controls were obtained after adrenalectomy, respectively. VAT was stored at -80°C and total RNA was 137 isolated following the TRIZOL RNA isolation protocol (Invitrogen). Quality of RNA was analyzed by 138 capillary electrophoresis on an Agilent System Agilent 2100 was determined. RNA-seq was performed 139 by Novogen (UK) on an Illumina Novaseq 600. Data quality control was performed on the basis of 140 Pearson correlation and samples with a low correlation (<0.6) were removed (2 samples). The pairedend data was aligned to the human genome GRCh38 (hg38) using hisat2 [29]. Differential expression 141 analysis between the control group and the CS patients, as well as between the two groups of CS 142 143 patients were performed using DESeq2 [30]. Differentially expressed genes (DEG) were defined using 144 a p.value of <0.05 and a log2foldchange of >1 as criteria. Volcano plots for the DEG were generated 145 using R (3.6.3 and 4.04). Heatmaps were generated using MORPHEUS (Morpheus, 146 https://software.broadinstitute.org/morpheus), and ComplexHeatmap [31]. Data on protein origin 147 (secreted, membrane bound, intracellular) was obtained from The Human Protein Atlas [32]. Principal 148 component analysis was performed using the pcaExplorer package [33]. Pathway analysis was 149 performed using the DEG previously defined with ENRICHR [34]. Top 4 hits are shown sorted by p.value 150 for the Elsevier pathway analysis and the gene ontology biological process analysis. Epigenetic 151 Landscape In Silico deletion Analysis (LISA) was performed using the top most 500 DEG, sorted by 152 p.value [35]. Gene set enrichment analysis (GSEA) was performed using the GSEA 4.2.3 version of the local application [36]. In silico cytometry was performed using the Cibersortx web application [37]. For 153

this purpose, signature matrices were generated using all the available VAT human single cell data of
lean patients from [38] to estimate cell type populations in our bulk RNA-seq approach. Data was
processed using Galaxy Europe [39].

### 157 Sample Data Availability

158 Sequencing data was uploaded to the GEO database and is available under GSE218965.

## 159 Immunohistochemistry

160 Sections with VAT from CS patients and controls were rehydrated in xylene and an alcohol series. 161 Subsequently antigen retrieval in citrate-based antigen retrieval solution (Sigma, C999) for 20 minutes 162 at 100°C was applied. Samples were blocked using a ready-to-use blocking solution (Milipore, 20773) 163 and incubated with antibody (1:200 Cd68 abcam KP1, 1:100 PDE4D Sigma-Aldrich (SAB4502128)) 164 diluted in blocking solution. Endogenous peroxidases were quenched with 0.03% v/v H<sub>2</sub>O<sub>2</sub> for 20 mins after which the samples were blocked using avidin/biotin blocking kit (Vector Laboratories SP-2001). 165 166 Sections where incubated with anti-rabbit, or anti-mouse biotinylated secondary antibody 1:800 (BA-167 1000 or BA-9200 Vector Laboratories) for 2 hours at 4°C. After washing with PBS, samples were 168 incubated with streptavidin-conjugated horseradish peroxidase (SA-5004 Vector laboratories 1:300 in PBS 0.1% Tween-20) for 1 hour at 4°C. Color detection on the samples was performed using 3,3'-820 169 170 diaminobenzidine (ImmPACT DAB SK-4100, Vector Laboratories) and nuclei with Hematoxylin solution 171 (H3401 Vector Laboratories). Sections were then dehydrated and mounted using Eukitt (Langenbrinck 04-0001). Images were acquired using 10x magnification on an Olympus BX41 microscope. 172

173

#### 174 Blood vessel quantification

Blood vessel were counted on whole tissue slides from each patient and the number of blood vesselswas normalized to the whole tissue area.

177

### 178 Image Analysis

Pictures from IHC were analyzed using ImageJ Fiji software [40]. Quantification was performed asstained area/total area of the pictures and shown in %.

181

### 182 Statistical Analysis

Statistics were performed using GraphPad 9 and R (3.6.3 and 4.0.4). Categorical data was analyzed using Fisher exact test and continuous data was analyzed using Mann-Whitney test or two-way ANOVA. Correlations were performed using GraphPad with simple linear regression model. P.value of below 0.05 was consider a significant effect.

#### 188 Results

#### 189 Visceral Adipose Tissue transcriptome is altered by active Cushing's syndrome

To clarify specific gene signatures in VAT of patients with Cushing's syndrome we collected VAT from 12 patients with CPA and 5 patients with NFAT. Clinical data are shown in **Table 1**. As expected, patients with CS had higher blood pressure values compared to controls and an elevated homeostatic model assessment for insulin resistance index (HOMA-IR). Body mass index (BMI) and serum potassium were comparable in both groups.

195 Expression profiling by RNAseq identified 1073 genes differentially regulated as shown by the volcano blot (Figure 1A) and the principal component analysis (PCA) (Figure S1A). Elsevier Pathway analysis of 196 197 these differentially expressed genes (DEG) showed hypertension and colitis as the most regulated 198 pathways, while gene ontology analysis revealed a differentially regulation of protein folding 199 dependent on chaperons (Figure 1B). The top term in the Pathway enrichment was arterial 200 hypertension, which includes a wide variety of genes of which the differentially expressed ones include 201 REN, VWF and VEGFA (Figure 1C). To investigate the potential regulators of these DEG, we performed 202 an epigenetic landscape in silico deletion analysis (LISA) [35]. Here we found that the most likely 203 transcription factors regulating the DEGs were not the suspected cortisol activated transcription 204 factors GR (NR3C1) or MR (NR3C2), but rather EGR3, TERC, CTCF, and the ESR1 (estrogen receptor), in 205 line with previously published data sets (Figure S1B) [41].

206 To further dissect the effects of active CS on adipose tissue we performed an in silico cytometry 207 approach (Cibersortx), to estimate the putative changes in cell populations [37]. This approach 208 revealed different abundance in four cell populations during active CS (Figure 2A, C, E). Monocytes are 209 macrophage precursors from the blood stream and are actively infiltrating tissues, including the VAT 210 [42]. Cibersortx analysis showed an increase of monocytes in the VAT from CS patients, this was further 211 supported by IHC for CD68 and macrophage marker which was also increased in the tissue (Figure 2B). 212 Strikingly gene set enrichment analysis (GSEA) from the controls versus the CS patients showed a 213 decrease in TNFA signaling via NFKB in addition to many inflammation associated genes like DUSP1, 214 IL6 and NFKB1 being downregulated and anti-inflammatory genes like SPHK1 being upregulated.

Furthermore, a fraction of the population of adipocyte stem- and precursor cells was downregulated in patients with active CS, which are defined as adipocyte stem- and precursor cells (hASPC6) (**Figure 2C**) [38], paralleled by downregulation in the GSEA for adipogenesis, including markers for adipocyte function and health, like *ADIPOQ*, *CD36* and *PPARG* (**Figure 2C**). This population of hASPCs was characterized by a high expression of *PDE4D*, a key marker gene for this cell population [38]. The expression of PDE4D was confirmed in the adipocyte stem- and precursor cell population from the

CibersortX analysis (Figure S2D) and further by staining for it in the adipose tissue of the patients with
 IHC (Figure 2D).

223 Finally, we observed an increase in the abundance of endothelial cells and reduction of smooth muscle 224 cells, suggesting an effect on the local vascular system. This is also confirmed by GSEA, which showed 225 that the smooth muscle cell function and the local renin-angiotensin-aldosterone system (RAAS) were 226 decreased (Figure 2E). In addition, we also found that the abundance of blood vessels (BV) was strongly 227 reduced in the adipose tissue from patients with CS compared to NFAT control tissue (Figure 2E). This 228 was also confirmed as many components of the RAAS like REN, AGTR1 and VWF were regulated during 229 CS. These data suggest a wide range of physiological consequences on the adipose tissue during CS, 230 with major cell populations and important pathways and genes being affected.

231

# 232 Gene expression reveals a correlation between VAT transcriptome and blood pressure.

233 Unbiased clustering through PCA of the gene profiles of all samples indicated that the group of CS patients does not have a homogenous phenotype (Figure S2A reordered from Figure S1A). This is 234 235 further confirmed by hierarchal clustering of the DEG between CS and NFAT control patients, in which 236 we observed 3 clearly defined clusters (Figure 3A). Cluster 1 represented continuously downregulated 237 genes and involved a high number of genes encoding secreted proteins, involved in resolution of 238 inflammation and hypertension. In contrast mRNAs in cluster 2 and 3 were upregulated, but genes in 239 cluster 3 are only upregulated in a CS subgroup. These subgroups of CS patients showed no difference 240 in age, body composition, diabetic metabolic state or the severity of hypercortisolism measured by 241 UFC, LNSC and LDDST (Figure 3B, Figure S2B). However, the subgroups of CS patients (Cluster 3 low 242 and Cluster 3 high expression) were strongly different in their hypertensive phenotype during glucocorticoid excess. While the first subgroup (Cluster 3 low expressed, now designated as CS<sup>Low</sup>) was 243 244 characterized by a non-significant, slightly higher blood pressure compared to the NFAT controls, the second subgroup (Cluster 3 high expressed, now designated as CS<sup>High</sup>) had significantly higher blood 245 246 pressure levels with a pronounced hypertensive phenotype (Figure 3B, Figure S2B). This effect was 247 independent of antihypertensive medication, as the number of patients receiving antihypertensive drugs was comparable in both subgroups of CS patients (CS<sup>Low</sup>: 4/6, CS<sup>High</sup>: 5/6) (Figure S2C). 248

Between the gene signatures assigned to the CS<sup>Low</sup> group and CS<sup>High</sup> group we observed 4883 DEGs.
Pathway analysis revealed a high score of adiponectin synthesis and other adipokines (Figure S3A, B).
Similar to the total comparison of controls with CS patients we found by LISA that neither GR (NR3C1)
nor MR (NR3C2) were among the top candidates for potential TF regulating the DEG (Figure S3C).
Rather PHF8, MAZ, CDK9 and MYC/MAX were among the relevant regulators.

254 The topmost regulated gene was renin (REN) responsible for the conversion of angiotensinogen to 255 angiotensin I. The RAAS is known to be altered in CS [13]. This gene was also regulated according to 256 the previously defined subgroups of patients with CS, although not reaching statistical significance 257 (Figure 4A). Intriguingly the expression of RAAS components in VAT like renin and others was shown 258 to be a major factor in obesity related blood pressure pathologies [24]. We found that the VAT gene 259 expression of REN correlated significantly with the systolic blood pressure of all patients included in 260 the study, with an R<sup>2</sup> of 0.237 (Figure 4B). Plasma renin and aldosterone levels were not significantly 261 different in CS patients compared with control patients, consistent with previous studies investigating 262 the systemic RAAS in CS, which reported plasma renin and aldosterone concentrations within the 263 normal or slightly below the normal range [13, 43-46]. Interestingly, plasma renin concentrations were significantly reduced in the CS<sup>High</sup> versus the CS<sup>Low</sup> subgroup, and the aldosterone to renin ratio 264 265 elevated, indicating a systemic endocrine response of the renal juxtaglomerular apparatus to an 266 abnormal high blood pressure and volume status (Figure 4C left). Noteworthy, REN gene expression in 267 VAT did not correlate with plasma renin concentrations measured in patients with CS (Figure 4D). 268 Aldosterone, aldosterone to renin ratio and serum potassium levels were not different between subgroups and compared to controls (Figure 4C right). Moreover, plasma renin concentrations were 269 270 not predictive of high blood pressure levels, as we observed no correlation between plasma renin 271 levels and blood pressure (Figure S3E).

Six months following curative surgery, both subgroups showed lower blood pressure values compared with the time of diagnosis, as expected (**Figure 4F**). Remarkably, there was still a trend towards higher blood pressure values in patients of CS<sup>High</sup> subgroup compared to CS<sup>Low</sup> (p=0.08) after 6 months in remission (Patients on BP drugs CS<sup>Low</sup>: 1/6, CS<sup>High</sup>: 1/6). This indicates a potential long-lasting effects of adipose tissue RAS components despite sustained biochemical remission of CS.

#### 278 Discussion

279 Management of patients with CS and the thereof caused long-term complications are still a major 280 challenge today [28, 47]. VAT taken as part of the adrenalectomy shows significant alterations in the 281 transcriptome (**Figure 1**) compared to non-CS patients, as previously reported [41, 48]. Consistent with 282 previous studies, our study highlights the profound effects of chronic cortisol excess on adipose tissue 283 gene expression. We discovered a unique gene expression signature in VAT that is associated with a 284 pronounced hypertensive phenotype in patients with adrenal CS that persisted even despite remission 285 of hypercortisolism.

286 In subcutaneous adipose tissue the patients with CS disease did show more metabolic alterations in 287 regard to lipogenesis and glucose oxidation [48], which was not commonly observed in the VAT in our 288 study. However, we observed some similar effects including an increase in fatty acid synthase (FASN) 289 and leptin (LEP) in CS patients. This could be due to the fact that the subcutaneous adipose tissue and 290 visceral fat have strong differences in their metabolic activity, especially regarding lipolysis [49]. Our 291 analysis indicated that adipocyte stem- and precursor cells were decreased in CS, as well as a strong 292 regulation of important factors for adipocyte differentiation like adiponectin (ADIPOQ) and 293 peroxisome proliferator-activated receptor-gamma (PPARG). This suggests an attenuated adipocyte 294 differentiation and adipogenesis of precursor cells [50]. As patients with CS have a strong change in fat 295 cell distribution and body weight gain [51], one of the reasons for this might be a changed adipose 296 tissue identity caused by cortisol excess.

297 It has been proposed that in VAT of patients with CS, the hypercortisolism has strong effects on 298 inflammatory genes and immune cell infiltration, with studies showing an increased number of infiltrating macrophages (CD68 positive cells) [52]. We could also observe and increased number of 299 300 infiltrating monocytes and macrophages (Figure 2A). In contrast to other studies, we did not observe 301 a low-grade inflammation but rather a suppression of inflammatory and increased expression of anti-302 inflammatory markers of macrophages and inflammation. The most common observation for 303 inflammatory effects in the VAT of CS patients has been an increase in Cd11c (ITGAX) a marker for an 304 increased proinflammatory state, which we did not observe in our patient cohort [41, 52]. In our study 305 we did, however, see a strong downregulation of inflammatory cytokines like II6 (IL6) and Cxcl3 (CXCL3) 306 as well as a downregulation of the inflammatory NFKB pathway and MAPK pathways. This contrast 307 could be explained that both studies showing an increase in ITGAX were sex mixed cohorts of patients, 308 while our study only focuses on female patients.

A major challenge in patients with CS is the management of blood pressure [5, 53]. More so it was intriguing that we saw strong effects on endothelia cells and smooth muscle cell abundance, as well as important genes for the vascular system like Vegfa (VEGFA) and VWF (VWF). It has already been shown 312 that cortisol excess can lead to an increase of thickness in arteries and therefore modulate systemic 313 blood pressure and persistent modulation of the vascular system, even after achieving remission of 314 endogenous cortisol excess [54-57]. While some of these vascular changes revert after the remission 315 some persists, like the plaque formation [20, 58]. Furthermore, we saw a strong regulation of 316 components of the RAAS in the VAT. For patients suffering from hypertension caused by obesity it was 317 shown that local RAAS activity was a major factor in contribution to hypertension, irrespective of 318 systemic regulation [59, 60]. In obesity, angiotensinogen levels are known to be elevated and VAT-319 derived angiotensinogen can enter the circulation, leading to an elevated blood pressure through the 320 actions of angiotensin II. Here, the local activation of glucocorticoid action in adipose tissue of patients with obesity is proposed to induce activation of RAS [22]. Recently, a positive correlation between BMI 321 322 and plasma angiotensinogen concentrations in patients with CS was observed [13].

We could further dissect this effect in correlating the VAT gene expression to patient features and show that within our group of CS patients the gene expression in VAT was correlated with the severity of the hypertensive phenotype (**Figure 3**). mRNA expression of Renin (REN) in VAT was strongly correlated with the systemic blood pressure (**Figure 4**). Interestingly this was independent of the severity of endogenous glucocorticoid excess.

328 The tissue RAS and the circulating RAS are in a state of constant interaction [22, 61]. Activation and/or 329 modulation of the RAS is known to be a mechanism of glucocorticoid-induced hypertension in patients 330 with CS [11, 16]. Despite elevated angiotensinogen (renin substrate) levels observed in CS [62], levels 331 of renin activity, renin concentration, angiotensin II and aldosterone are reported in the normal or below the normal range [13, 43-46]. This is interpreted as an overall increased throughput of the RAS 332 333 and/or the consequence of increased glucocorticoid-mediated mineralocorticoid receptor stimulation 334 and thus renin suppression [13, 63]. Moreover, patients with CS showed an increased pressor response 335 to angiotensin II [64, 65], and there is evidence that glucocorticoids increase angiotensin II type 1 336 receptor gene expression [66, 67]. Due to the observed generalized upregulation of the RAS in patients 337 with CS, angiotensin-converting enzyme inhibitors or angiotensin receptor blockers are recommended 338 as first-line approach for blood pressure control in CS [5].

In line with previous studies, our patients with active CS showed no significant difference in plasma renin and aldosterone concentrations compared to controls (**Figure 4C**). Interestingly, in the CS<sup>High</sup> subgroup, we observed significantly decreased plasma renin concentrations compared to the the CS<sup>Low</sup> subgroup. Since aldosterone and potassium levels are normal in both subgroups, showing no difference (**Figure 4C and S3D**), we assume a relative functional mineralocorticoid excess state in relation to blood pressure and systemic volume, which induces negative feedback regulation at kidney level decreasing systemic renin levels. This condition has also been described primarily in patients with 346 ectopic CS [63, 68, 69]. Furthermore, several studies demonstrated that sodium reabsorption and 347 blood volume expansion through mineralocorticoid receptor activation is insufficient to explain the development of glucocorticoid-induced hypertension [63, 70-73]. Since we observed a unique VAT 348 349 gene expression profile with increased REN expression associated with a hypertensive phenotype and 350 lower plasma renin levels in a subset of CS patients, we postulate a local overactivity of the RAS in VAT. 351 This RAS activation, as suggested by others [13, 63], could lead to low plasma renin levels through 352 increased angiotensin production and aldosterone synthesis, via a hypothesized negative feedback mechanism to limit excessive angiotensin II production [74]. 353

354 Remarkably, in the study by van der Pas and colleagues [13], plasma concentrations of 355 angiotensinogen, renin and aldosterone had not changed despite biochemical remission by medical 356 therapy, indicating long-lasting effects on plasma RAS components that may be responsible for partial 357 persistence of glucocorticoid-induced hypertension. Despite successful treatment of CS, about one 358 third of patients have persistent hypertension [12, 20, 64]. As predictive factors for persistent 359 hypertension, older age, higher BMI at baseline and a longer estimated duration of hypercortisolism 360 were observed [17]. Of note, the severity of hypercortisolism does not seem to affect the severity of 361 hypertension or the remission status of hypertension after successful treatment of CS [11-13, 17]. This is consistent with our observation that CS<sup>High</sup> and CS<sup>Low</sup> subgroup subgroups do not differ in the degree 362 of hypercortisolism (Figure 3B and S2B). In our follow-up visits 6 months after adrenalectomy due to 363 adrenal CS, a difference in blood pressure was still found between CS subgroups CS<sup>High</sup> and CS<sup>Low</sup>, which 364 365 may suggest an association of VAT RAS modulation and the persistence of glucocorticoid-induced 366 hypertension. This could be either of epigenetic nature, as it has been previously reported that CS 367 patients also show a changed epigenetic landscape or genetic nature exacerbated by the excess 368 cortisol [41]. Here it was shown that markers for epigenetic gene activation (H3K27ac) and gene 369 repression (H3K4me3) were altered during active CS.

We propose that local RAAS activity induced by local excess of cortisol, independent from systemic
 regulation could alter the systemic blood pressure and contribution to the hypertension observed in
 CS patients.

A limitation of our study is, that our patients used a variety of antihypertensive drugs, most of which are known to interfere with plasma concentrations of the RAS. However, plasma RAS components in patients with CS were not shown to be significantly affected by angiotensin-converting enzyme inhibitors, angiotensin receptor blockers or  $\beta$ -adrenoceptor blockers [13]. But of course, RAS blockade or  $\beta$ -adrenoceptor blockers could also have an effects of RAS components in VAT.

Why the subgroups of patients with CS determined on the basis of gene expression in VAT form
 remains unclear. Differences in local glucocorticoid levels, e.g., due to altered 11β hydroxysteroid

- 380 dehydrogenase type 1 activity, are possible [63].  $11\beta$  hydroxysteroid dehydrogenase type 1 is found
- primarily in liver and adipose tissue and appears to have a role in arterial hypertension [63, 69, 75].
- 382

## 383 Author Contributions

- 384 US, JPT and MR conceptualized the study and planned experiments. US performed bioinformatic
- analyses. US and FV performed molecular biology assays. GC provided critical methods and protocols.
- 386 JPT and MR supervised the work. US, FV, MR and JPT wrote the manuscript. All authors approved the
- 387 manuscript.

# 388 **Declaration of interest:**

389 The authors have nothing to disclose.

## 390 Acknowledgments

391 This work was funded by the Deutsche Forschungsgemeinschaft (DFG) within the collaborative 392 Research Centre 1506 Aging at Interfaces at the Project C05 (Project Number 450627322) to J.T. M.R. 393 received grant support for the German Cushing's Registry CUSTODES by the Else Kröner-Fresenius 394 Stiftung (2012\_A103 and 2015\_A228), by the Deutsche Forschungsgemeinschaft (DFG, German 395 Research Foundation, Projektnummer: 314061271-TRR 205) and by the European Research Council 396 under the European Union Horizon 2020 research and innovation program (grant agreement No. 397 694913). F.V. is supported by the Deutsche Forschungsgemeinschaft (DFG, German Research Foundation, project number: 413635475) and the Munich Clinician Scientist Program (MCSP) of the 398 399 LMU München.

# 401 References

403 404 405	[1]	L. K. Nieman <i>et al.</i> , "The diagnosis of Cushing's syndrome: an Endocrine Society Clinical Practice Guideline," <i>J Clin Endocrinol Metab</i> , vol. 93, no. 5, pp. 1526-40, May 2008, doi: 10.1210/ic.2008-0125
406 407 408	[2]	E. Valassi <i>et al.</i> , "High mortality within 90 days of diagnosis in patients with Cushing's syndrome: results from the ERCUSYN registry," <i>Eur J Endocrinol</i> , vol. 181, no. 5, pp. 461-472, Nov 2019, doi: 10.1530/EJE-19-0464.
409 410 411	[3]	O. M. Dekkers <i>et al.</i> , "Multisystem morbidity and mortality in Cushing's syndrome: a cohort study," <i>J Clin Endocrinol Metab</i> , vol. 98, no. 6, pp. 2277-84, Jun 2013, doi: 10.1210/jc.2012-3582.
412 413 414	[4]	E. Papakokkinou <i>et al.</i> , "Excess Morbidity Persists in Patients With Cushing's Disease During Long-term Remission: A Swedish Nationwide Study," <i>J Clin Endocrinol Metab</i> , vol. 105, no. 8, Aug 1 2020. doi: 10.1210/clinem/dgaa291
415 416 417 418	[5]	F. Fallo <i>et al.</i> , "Diagnosis and management of hypertension in patients with Cushing's syndrome: a position statement and consensus of the Working Group on Endocrine Hypertension of the European Society of Hypertension," <i>J Hypertens</i> , Aug 9 2022, doi: 10.1097/HJH 00000000003252
419 420 421	[6]	E. Valassi <i>et al.</i> , "The European Registry on Cushing's syndrome: 2-year experience. Baseline demographic and clinical characteristics," <i>Eur J Endocrinol</i> , vol. 165, no. 3, pp. 383-92, Sep 2011. doi: 10.1530/EJE-11-0272.
422 423 424	[7]	D. Hirsch <i>et al.</i> , "Cushing's syndrome: comparison between Cushing's disease and adrenal Cushing's," <i>Endocrine</i> , vol. 62, no. 3, pp. 712-720, Dec 2018, doi: 10.1007/s12020-018-1709- y.
425 426 427	[8]	F. Gokosmanoglu, A. Guzel, E. K. Kan, and H. Atmaca, "Increased prevalence of obstructive sleep apnea in patients with Cushing's syndrome compared with weight- and age-matched controls." <i>Eur J Endocrinol</i> , vol. 176, no. 3, pp. 267-272, Mar 2017, doi: 10.1530/EJE-16-0815.
428 429 430	[9]	M. Zilio <i>et al.</i> , "Diagnosis and complications of Cushing's disease: gender-related differences," <i>Clin Endocrinol (Oxf)</i> , vol. 80, no. 3, pp. 403-10, Mar 2014, doi: 10.1111/cen.12299.
431 432 433 434	[10]	F. Pecori Giraldi, M. Moro, F. Cavagnini, and E. Study Group on the Hypothalamo-Pituitary- Adrenal Axis of the Italian Society of, "Gender-related differences in the presentation and course of Cushing's disease," <i>J Clin Endocrinol Metab</i> , vol. 88, no. 4, pp. 1554-8, Apr 2003, doi: 10.1210/jc.2002-021518.
435 436 437	[11]	M. Barbot, F. Ceccato, and C. Scaroni, "The Pathophysiology and Treatment of Hypertension in Patients With Cushing's Syndrome," <i>Front Endocrinol (Lausanne),</i> vol. 10, p. 321, 2019, doi: 10.3389/fendo.2019.00321.
438 439 440 441	[12]	R. Giordano <i>et al.</i> , "Metabolic and cardiovascular outcomes in patients with Cushing's syndrome of different aetiologies during active disease and 1 year after remission," <i>Clin Endocrinol (Oxf)</i> , vol. 75, no. 3, pp. 354-60, Sep 2011, doi: 10.1111/j.1365-2265.2011.04055.x.
442 443 444	[13]	R. van der Pas <i>et al.</i> , "Cushing's disease and hypertension: in vivo and in vitro study of the role of the renin-angiotensin-aldosterone system and effects of medical therapy," <i>Eur J Endocrinol</i> , vol. 170, no. 2, pp. 181-91, Feb 2014, doi: 10.1530/EJE-13-0477.
445 446 447	[14]	R. N. Clayton, D. Raskauskiene, R. C. Reulen, and P. W. Jones, "Mortality and morbidity in Cushing's disease over 50 years in Stoke-on-Trent, UK: audit and meta-analysis of literature," <i>J Clin Endocrinol Metab</i> , vol. 96, no. 3, pp. 632-42, Mar 2011, doi: 10.1210/jc.2010-1942.
448 449 450	[15]	M. J. Bolland <i>et al.</i> , "Mortality and morbidity in Cushing's syndrome in New Zealand," <i>Clin Endocrinol (Oxf)</i> , vol. 75, no. 4, pp. 436-42, Oct 2011, doi: 10.1111/j.1365-2265.2011.04124.x.

451	[16]	M. V. Cicala and F. Mantero, "Hypertension in Cushing's syndrome: from pathogenesis to
452	••	treatment," <i>Neuroendocrinology,</i> vol. 92 Suppl 1, pp. 44-9, 2010, doi: 10.1159/000314315.
453	[17]	S. Jha, N. Sinaii, R. N. McGlotten, and L. K. Nieman, "Remission of hypertension after surgical
454		cure of Cushing's syndrome," <i>Clin Endocrinol (Oxf),</i> vol. 92, no. 2, pp. 124-130, Feb 2020, doi:
455		10.1111/cen.14129.
456	[18]	F. Vogel <i>et al.</i> , "Persisting muscle dysfunction in Cushing's syndrome despite biochemical
457		remission," J Clin Endocrinol Metab, Sep 3 2020, doi: 10.1210/clinem/dgaa625.
458	[19]	M. H. Schernthaner-Reiter et al., "Factors predicting long-term comorbidities in patients with
459		Cushing's syndrome in remission," <i>Endocrine,</i> vol. 64, no. 1, pp. 157-168, Apr 2019, doi:
460		10.1007/s12020-018-1819-6.
461	[20]	A. Colao et al., "Persistence of increased cardiovascular risk in patients with Cushing's disease
462		after five years of successful cure," J Clin Endocrinol Metab, vol. 84, no. 8, pp. 2664-72, Aug
463		1999, doi: 10.1210/jcem.84.8.5896.
464	[21]	F. Ferrau and M. Korbonits, "Metabolic Syndrome in Cushing's Syndrome Patients," Front
465		<i>Horm Res,</i> vol. 49, pp. 85-103, 2018, doi: 10.1159/000486002.
466	[22]	V. Kotsis, S. Stabouli, S. Papakatsika, Z. Rizos, and G. Parati, "Mechanisms of obesity-induced
467		hypertension," <i>Hypertens Res,</i> vol. 33, no. 5, pp. 386-93, May 2010, doi: 10.1038/hr.2010.9.
468	[23]	M. Boscaro, G. Giacchetti, and V. Ronconi, "Visceral adipose tissue: emerging role of gluco-
469		and mineralocorticoid hormones in the setting of cardiometabolic alterations," Ann NY Acad
470		<i>Sci,</i> vol. 1264, pp. 87-102, Aug 2012, doi: 10.1111/j.1749-6632.2012.06597.x.
471	[24]	L. A. Cassis, S. B. Police, F. Yiannikouris, and S. E. Thatcher, "Local adipose tissue renin-
472		angiotensin system," <i>Curr Hypertens Rep,</i> vol. 10, no. 2, pp. 93-8, Apr 2008, doi:
473		10.1007/s11906-008-0019-9.
474	[25]	M. Fassnacht et al., "Management of adrenal incidentalomas: European Society of
475		Endocrinology Clinical Practice Guideline in collaboration with the European Network for the
476		Study of Adrenal Tumors," <i>Eur J Endocrinol,</i> vol. 175, no. 2, pp. G1-G34, Aug 2016, doi:
477		10.1530/EJE-16-0467.
478	[26]	L. T. Braun <i>et al.</i> , "Whom should we screen for Cushing's syndrome: The Endocrine Society
479		Practice Guideline Recommendations 2008 revisited," J Clin Endocrinol Metab, Jun 22 2022,
480		doi: 10.1210/clinem/dgac379.
481	[27]	A. Prete et al., "Cardiometabolic Disease Burden and Steroid Excretion in Benign Adrenal
482		Tumors : A Cross-Sectional Multicenter Study," Ann Intern Med, Jan 4 2022, doi:
483		10.7326/M21-1737.
484	[28]	C. H. Ahn, J. H. Kim, M. Y. Park, and S. W. Kim, "Epidemiology and Comorbidity of Adrenal
485		Cushing Syndrome: A Nationwide Cohort Study," <i>J Clin Endocrinol Metab</i> , vol. 106, no. 3, pp.
486		e1362-e1372, Mar 8 2021, doi: 10.1210/clinem/dgaa752.
487	[29]	D. Kim, J. M. Paggi, C. Park, C. Bennett, and S. L. Salzberg, "Graph-based genome alignment
488		and genotyping with HISAT2 and HISAT-genotype," Nat Biotechnol, vol. 37, no. 8, pp. 907-
489		915, Aug 2019, doi: 10.1038/s41587-019-0201-4.
490	[30]	M. I. Love, W. Huber, and S. Anders, "Moderated estimation of fold change and dispersion
491		for RNA-seq data with DESeq2," <i>Genome Biol</i> , vol. 15, no. 12, p. 550, 2014, doi:
492		10.1186/s13059-014-0550-8.
493	[31]	Z. Gu, R. Eils, and M. Schlesner, "Complex heatmaps reveal patterns and correlations in
494		multidimensional genomic data," <i>Bioinformatics</i> , vol. 32, no. 18, pp. 2847-9, Sep 15 2016,
495		doi: 10.1093/bioinformatics/btw313.
496	[32]	M. Uhlen <i>et al.</i> , "The human secretome," <i>Sci Signal</i> , vol. 12, no. 609, Nov 26 2019, doi:
497		10.1126/scisignal.aaz0274.
498	[33]	F. Marini and H. Binder, "pcaExplorer: an R/Bioconductor package for interacting with RNA-
499		seq principal components," BMC Bioinformatics, vol. 20, no. 1, p. 331. Jun 13 2019. doi:
500		10.1186/s12859-019-2879-1.
501	[34]	E. Y. Chen <i>et al.</i> , "Enrichr: interactive and collaborative HTML5 gene list enrichment analysis
502		tool," <i>BMC Bioinformatics,</i> vol. 14, p. 128, Apr 15 2013, doi: 10.1186/1471-2105-14-128.

503 [35] Q. Qin et al., "Lisa: inferring transcriptional regulators through integrative modeling of public 504 chromatin accessibility and ChIP-seq data," Genome Biol, vol. 21, no. 1, p. 32, Feb 7 2020, 505 doi: 10.1186/s13059-020-1934-6. 506 [36] A. Subramanian et al., "Gene set enrichment analysis: a knowledge-based approach for 507 interpreting genome-wide expression profiles," Proc Natl Acad Sci U S A, vol. 102, no. 43, pp. 508 15545-50, Oct 25 2005, doi: 10.1073/pnas.0506580102. 509 [37] A. M. Newman et al., "Determining cell type abundance and expression from bulk tissues 510 with digital cytometry," Nat Biotechnol, vol. 37, no. 7, pp. 773-782, Jul 2019, doi: 10.1038/s41587-019-0114-2. 511 512 [38] M. P. Emont et al., "A single-cell atlas of human and mouse white adipose tissue," Nature, 513 vol. 603, no. 7903, pp. 926-933, Mar 2022, doi: 10.1038/s41586-022-04518-2. 514 [39] E. Afgan et al., "The Galaxy platform for accessible, reproducible and collaborative 515 biomedical analyses: 2018 update," Nucleic Acids Res, vol. 46, no. W1, pp. W537-W544, Jul 2 516 2018, doi: 10.1093/nar/gky379. 517 [40] J. Schindelin et al., "Fiji: an open-source platform for biological-image analysis," Nat 518 Methods, vol. 9, no. 7, pp. 676-82, Jun 28 2012, doi: 10.1038/nmeth.2019. 519 [41] G. Garcia-Eguren et al., "Glucocorticoid-induced fingerprints on visceral adipose tissue transcriptome and epigenome," J Clin Endocrinol Metab, Sep 6 2021, doi: 520 521 10.1210/clinem/dgab662. 522 [42] L. Boutens and R. Stienstra, "Adipose tissue macrophages: going off track during obesity," 523 Diabetologia, vol. 59, no. 5, pp. 879-94, May 2016, doi: 10.1007/s00125-016-3904-9. 524 [43] F. Mantero, D. Armanini, and M. Boscaro, "Plasma renin activity and urinary aldosterone in 525 Cushing's syndrome," Horm Metab Res, vol. 10, no. 1, pp. 65-71, Jan 1978, doi: 10.1055/s-526 0028-1093484. A. Ganguly, M. H. Weinberger, and C. E. Grim, "The renin-angiotensin-aldosterone system in 527 [44] 528 Cushing's syndrome and pheochromocytoma," Horm Res, vol. 17, no. 1, pp. 1-10, 1983, doi: 529 10.1159/000179668. 530 [45] C. M. Ritchie et al., "Studies on the pathogenesis of hypertension in Cushing's disease and 531 acromegaly," Q J Med, vol. 76, no. 280, pp. 855-67, Aug 1990. [Online]. Available: 532 https://www.ncbi.nlm.nih.gov/pubmed/2217688. 533 T. Saruta, H. Suzuki, M. Handa, Y. Igarashi, K. Kondo, and S. Senba, "Multiple factors [46] 534 contribute to the pathogenesis of hypertension in Cushing's syndrome," J Clin Endocrinol 535 Metab, vol. 62, no. 2, pp. 275-9, Feb 1986, doi: 10.1210/jcem-62-2-275. 536 [47] L. T. Braun, F. Vogel, and M. Reincke, "Long-term morbidity and mortality in patients with 537 Cushing's syndrome," J Neuroendocrinol, vol. 34, no. 8, p. e13113, Aug 2022, doi: 538 10.1111/jne.13113. 539 [48] I. Hochberg et al., "Gene expression changes in subcutaneous adipose tissue due to Cushing's 540 disease," J Mol Endocrinol, vol. 55, no. 2, pp. 81-94, Oct 2015, doi: 10.1530/JME-15-0119. 541 [49] M. M. Ibrahim, "Subcutaneous and visceral adipose tissue: structural and functional differences," Obes Rev, vol. 11, no. 1, pp. 11-8, Jan 2010, doi: 10.1111/j.1467-542 543 789X.2009.00623.x. 544 [50] A. Chawla, E. J. Schwarz, D. D. Dimaculangan, and M. A. Lazar, "Peroxisome proliferator-545 activated receptor (PPAR) gamma: adipose-predominant expression and induction early in 546 adipocyte differentiation," Endocrinology, vol. 135, no. 2, pp. 798-800, Aug 1994, doi: 547 10.1210/endo.135.2.8033830. 548 [51] D. Delivanis et al., "Abnormal body composition in patients with adrenal adenomas," Eur J 549 Endocrinol, Aug 1 2021, doi: 10.1530/EJE-21-0458. 550 I. T. Lee *et al.*, "Active Cushing Disease Is Characterized by Increased Adipose Tissue [52] 551 Macrophage Presence," J Clin Endocrinol Metab, vol. 104, no. 6, pp. 2453-2461, Jun 1 2019, 552 doi: 10.1210/jc.2018-02552. 553 [53] A. Coulden, R. Hamblin, J. Wass, and N. Karavitaki, "Cardiovascular health and mortality in 554 Cushing's disease," Pituitary, Jul 22 2022, doi: 10.1007/s11102-022-01258-4.

555	[54]	A. Faggiano <i>et al.</i> , "Cardiovascular risk factors and common carotid artery caliber and
556		stiffness in patients with Cushing's disease during active disease and 1 year after disease
557		remission," <i>J Clin Endocrinol Metab,</i> vol. 88, no. 6, pp. 2527-33, Jun 2003, doi:
558		10.1210/jc.2002-021558.
559	[55]	A. M. Isidori et al., "The hypertension of Cushing's syndrome: controversies in the
560		pathophysiology and focus on cardiovascular complications," <i>J Hypertens</i> , vol. 33, no. 1, pp.
561		44-60, Jan 2015, doi: 10.1097/HJH.0000000000000415.
562	[56]	D. Rizzoni <i>et al.</i> , "Hypertrophic remodeling of subcutaneous small resistance arteries in
563		patients with Cushing's syndrome," <i>J Clin Endocrinol Metab</i> , vol. 94, no. 12, pp. 5010-8, Dec
564		2009, doi: 10.1210/jc.2009-1588.
565	[57]	C. MacLeod, P. W. F. Hadoke, and M. Nixon, "Glucocorticoids: Fuelling the Fire of
566	[-]	Atherosclerosis or Therapeutic Extinguishers?." Int J Mol Sci. vol. 22, no. 14, Jul 16 2021, doi:
567		10.3390/iims22147622.
568	[58]	R. N. Clayton, "Cardiovascular complications of Cushings syndrome: Impact on morbidity and
569	[00]	mortality "I Neuroendocrinol n e13175 Jun 8 2022 doi: 10 1111/ine 13175
570	[59]	G Giacchetti <i>et al.</i> "Overexpression of the renin-angiotensin system in human visceral
570	[33]	adipose tissue in normal and overweight subjects "Am I Hypertens vol 15 no 5 nn 381-8
571		May 2002 doi: 10.1016/c0805-7061(02)02257-4
572	[60]	S Engeli at al. "Weight loss and the renin-angiotensin-aldosterone system" Hypertension
575	[00]	vol 45 po 2 pp 256.62 Mar 2005 doi: 10.1161/01 HVD 0000154261 47692 d2
574	[61]	Vol. 45, 110. 5, pp. 550-02, Wal 2005, uol. 10.1101/01.HTP.0000154501.47085.us.
575	[01]	D. J. Campbell, Circulating and tissue angiotensin systems, <i>J Cirin Invest</i> , vol. 79, no. 1, pp. 1-
5/0	[(2)]	6, Jan 1987, doi: 10.11/2/JCI112/08.
5//	[62]	C. Kiett <i>et al.</i> , Regulation of nepatic anglotensinogen synthesis and secretion by steroid
578		normones," <i>Endocrinology</i> , vol. 130, no. 6, pp. 3660-8, Jun 1992, doi:
579	[60]	10.1210/endo.130.6.159/163.
580	[63]	S. Baid and L. K. Nieman, "Glucocorticoid excess and hypertension," <i>Curr Hypertens Rep</i> , vol.
581		6, no. 6, pp. 493-9, Dec 2004, doi: 10.100//s11906-004-0046-0.
582	[64]	M. A. Magiakou, P. Smyrnaki, and G. P. Chrousos, "Hypertension in Cushing's syndrome,"
583		Best Pract Res Clin Endocrinol Metab, vol. 20, no. 3, pp. 467-82, Sep 2006, doi:
584		10.1016/j.beem.2006.07.006.
585	[65]	D. A. Scheuer and A. G. Bechtold, "Glucocorticoids potentiate central actions of angiotensin
586		to increase arterial pressure," Am J Physiol Regul Integr Comp Physiol, vol. 280, no. 6, pp.
587		R1719-26, Jun 2001, doi: 10.1152/ajpregu.2001.280.6.R1719.
588	[66]	A. Sato, H. Suzuki, M. Murakami, Y. Nakazato, Y. Iwaita, and T. Saruta, "Glucocorticoid
589		increases angiotensin II type 1 receptor and its gene expression," Hypertension, vol. 23, no. 1,
590		pp. 25-30, Jan 1994, doi: 10.1161/01.hyp.23.1.25.
591	[67]	H. Shibata, H. Suzuki, T. Maruyama, and T. Saruta, "Gene expression of angiotensin II
592		receptor in blood cells of Cushing's syndrome," Hypertension, vol. 26, no. 6 Pt 1, pp. 1003-10,
593		Dec 1995, doi: 10.1161/01.hyp.26.6.1003.
594	[68]	P. M. Stewart, B. R. Walker, G. Holder, D. O'Halloran, and C. H. Shackleton, "11 beta-
595		Hydroxysteroid dehydrogenase activity in Cushing's syndrome: explaining the
596		mineralocorticoid excess state of the ectopic adrenocorticotropin syndrome," J Clin
597		<i>Endocrinol Metab,</i> vol. 80, no. 12, pp. 3617-20, Dec 1995, doi: 10.1210/jcem.80.12.8530609.
598	[69]	M. Quinkler and P. M. Stewart, "Hypertension and the cortisol-cortisone shuttle," J Clin
599		<i>Endocrinol Metab,</i> vol. 88, no. 6, pp. 2384-92, Jun 2003, doi: 10.1210/jc.2003-030138.
600	[70]	L. K. Nieman <i>et al.</i> , "Successful treatment of Cushing's syndrome with the glucocorticoid
601		antagonist RU 486," <i>J Clin Endocrinol Metab,</i> vol. 61, no. 3, pp. 536-40, Sep 1985. doi:
602		10.1210/jcem-61-3-536.
603	[71]	G. J. Mangos, J. A. Whitworth, P. M. Williamson, and J. J. Kelly. "Glucocorticoids and the
604		kidney," <i>Nephrology (Carlton)</i> , vol. 8, no. 6, pp. 267-73, Dec 2003, doi: 10.1111/i.1440-
605		1797.2003.00215.x.

- [72] J. A. Whitworth, D. Gordon, J. Andrews, and B. A. Scoggins, "The hypertensive effect of
  synthetic glucocorticoids in man: role of sodium and volume," *J Hypertens*, vol. 7, no. 7, pp.
  537-49, Jul 1989, doi: 10.1097/00004872-198907000-00005.
- 609[73]M. Montrella-Waybill, J. N. Clore, A. C. Schoolwerth, and C. O. Watlington, "Evidence that610high dose cortisol-induced Na+ retention in man is not mediated by the mineralocorticoid611receptor," J Clin Endocrinol Metab, vol. 72, no. 5, pp. 1060-6, May 1991, doi: 10.1210/jcem-61272-5-1060.
- 613 [74] A. H. Danser, F. H. Derkx, H. W. Hense, X. Jeunemaitre, G. A. Riegger, and H. Schunkert,
  614 "Angiotensinogen (M235T) and angiotensin-converting enzyme (I/D) polymorphisms in
  615 association with plasma renin and prorenin levels," *J Hypertens,* vol. 16, no. 12 Pt 2, pp.
  616 1879-83, Dec 1998, doi: 10.1097/00004872-199816121-00005.
- 617 [75] P. Ferrari, E. Lovati, and F. J. Frey, "The role of the 11beta-hydroxysteroid dehydrogenase
  618 type 2 in human hypertension," *J Hypertens*, vol. 18, no. 3, pp. 241-8, Mar 2000, doi:
  619 10.1097/00004872-200018030-00001.

620

## 622 Table 1

	Non-functional adenoma (n=5)	Cushing's syndrome (n=12)	Reference	p.value
Age (years)	51 ± 5.4	44.5 ± 2.6		0.2448
Sex (female/male)	(5/0)	(12/0)		1
BMI (kg/m²)	27.36 ± 2.7	28.05 ± 2.0		0.9593
WC (cm)	-	93.07 ± 18.4		-
WHR	-	0.8417 ± 0.03	< 0.85	-
Fasting glucose (mg/dl)	106.4 ± 11.6	93.50 ± 2.7	60 - 99	0.3410
HbA1c (%)	5.500 ± 0.2	5.750 ± 0.1		0.3559
HOMA-IR	-	3.769 ± 0.9 (n=11)		-
Diast. BP (mmHG)	83.80 ± 1.9	92.40 ± 2.5		0.0493*
Syst. BP (mmHG)	126.80 ± 5.2	142 ± 3.6		0.0209*
Serum Potassium (mmol/L)	4.420 ± 0.16	4.167 ± 0.09	3.5 - 5.1	0.2015
LNSC (ng/ml)	0.9 ± 0.3 (n=3)	10.78 ± 4.2	≤ 1.5	0.0044**
UFC (μg/24h)	45 ± 0 (n=1)	434.3 ± 108.4	≤ 83.0	-
ACTH basal (pg/ml)	10.60 ± 1.9	2.917 ± 0.4	4 - 50	0,0002***
LDDST (µg/dl)	1.7 ± 0.8 (n=3)	16.94 ± 2.3	≤ 1.8	0.0044**
Cortisol basal	9.380 ± 1.7	17.59 ± 2.3		0.0255*

623

624**Table 1: Patient characteristics at the time of diagnosis.** Statistical significance was measured using625Mann-Witney U test for continuous data and Fishers exact test for categorical data. Data were626considered significant at  $p < 0.05^*$ ,  $p < 0.01^{**}$ ,  $p < 0.001^{***}$ ,  $p < 0.0001^{****}$ . Abbreviations: BMI, Body627mass index; WHR, Waist-to-hip ratio; WC, waist circumference; HbA1c, Hemoglobin A1c; HOMA-IR,628homeostatic model assessment for insulin resistance; BP, blood pressure; LNSC, late night salivary629cortisol; UFC, urinary free cortisol, LDDST, low dose dexamethasone suppression test. Data is shown630as SEM ± standard deviation.

# 632 Figures and Figure Legends



# 634 Figure 1



635

636 Figure 1: Transcriptome changes in female human patients during active adrenal Cushing syndrome 637 disease in visceral adipose tissue and control patients with non-functional adenomas. A) Volcano plot from 1073 DEG between female CS patients and matched control patients p.value < 0.05, log2FC 638 639 < 1. B) Elsevier Pathway analysis from DEG, top 4 terms shown and Gene Ontology biological process 640 analysis from DEG, top 4 terms shown (response to unfolded protein (GO:0006986), chaperone 641 cofactor-dependent protein refolding (GO:0051085), cellular response to heat (GO:0034605), 642 regulation of angiogenesis (GO:0045765)). C) Genes of the top changed Pathway Analysis terms shown 643 as heatmap with z-score D) In silico cell type distribution analysis using CibersortX from human patients 644 from Emont et al 2022.





647

Figure 2: In silico analysis together with histology reveals differential cell populations in the VAT of 648 649 female patients with CS and with non-functional adenomas as controls. A) Cell population of 650 monocyte sup population 2, with GSEA between CS patients and control patients. Representative 651 genes for the GSEA and cell population are shown. B) Histology for CD68 in patients with CS compared 652 to control patients (n=4-6). C) Cell population of adipocyte stem cell and precursor population 6, with 653 GSEA between CS and control patients. Representative genes for the GSEA and cell population are shown. D) Histology for PDE4D in patients with CS compared to control patients. E) Cell populations of 654 655 human endothelia cells and human smooth muscle cells, with GSEA between CS and control patients. Representative genes for the GSEA and cell population are shown. Blood vessels / tissue area were 656 657 counted. Statistical significance was measured using student t-test or Mann-Witney test. Data were considered significant at p < 0.05\*, p < 0.01\*\*, p < 0.001\*\*\*, p < 0.0001\*\*\*\*. 658





661

Figure 3: Visceral adipose tissue transcriptome of female CS patients reveals blood pressure heterogeneity. Female patients with non.functional adenomas served as controls A) Heatmap showing the DEG between CS and control patients after hierarchical clustering with Pathway Analysis from the 3 identified clusters. B) Patient data shown as boxplots after separation into the 3 groups given by the clustering Statistical significance was measured using two-way ANOVA. Data were considered significant at  $p < 0.05^*$ ,  $p < 0.01^{**}$ ,  $p < 0.001^{***}$ .

## 669 Figure 4



670

Figure 4: Renin and other components of the RAAS are regulated in VAT from a subset of female CS
patients and control systemic blood pressure. A) Renin (REN) gene expression from Fpkm shown. B)
Correlation between systemic systolic and diastolic blood pressure and REN (VAT) gene expression. C)
Renin and aldosterone serum levels. D) Correlation between Renin VAT gene expression and Renin
serum levels. E) Blood pressure decrease over time after surgery is shown for 6 months from both
subgroups of CS patients. Statistical significance was measured using two-way ANOVA or Mann-Witney
test. Data were considered significant at p < 0.05\*, p < 0.01\*\*, p < 0.001\*\*\*, p < 0.0001\*\*\*\*.</li>